Premium
Interleukin‐2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5‐fluorouracil resistance
Author(s) -
Cordel Sandrine,
Dupas Benoît,
Douillard JeanYves,
Meflah Khaled
Publication year - 1998
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19981209)78:6<735::aid-ijc11>3.0.co;2-6
Subject(s) - sodium butyrate , fluorouracil , medicine , metastasis , magnetic resonance imaging , butyrate , gastroenterology , liver cancer , immunotherapy , colorectal cancer , cancer , endocrinology , cell culture , biology , genetics , food science , radiology , fermentation
Abstract We studied the effect of immunotherapy using recombinant interleukin‐2 (rIL‐2) in combination with a differentiating agent, sodium butyrate (NaBut), on experimental 5‐fluorouracil (5‐FU)‐resistant liver metastasis from colorectal cancer in rats. For this purpose, we used direct liver injection of 5‐FU resistant cells, PRObR1, in syngeneic BDIX rats to establish liver tumors. The growth of liver metastasis was followed before and after NaBut/rIL‐2 treatment by magnetic resonance imaging (MRI). The presence of liver tumors was checked by MRI 7 days after tumor cell injection. Evaluable rats were then assigned randomly to a control and an experimental group. The different treatments were started on day 10 and administered intraperitoneally (i.p.). Combined NaBut/rIL‐2 treatment followed by MRI on days 56 and 91 was shown both to significantly reduce the growth of liver tumors and to prevent extrahepatic spread. In addition, NaBut/rIL‐2 treatment induced a complete regression in 50% of the rats which remained free of disease. Int. J. Cancer 78:735–739, 1998. © 1998 Wiley‐Liss, Inc.